AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14622826 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation (tape)
Number of subjects: 0
Study 14622826 — intervention group
Group type: COMPARATOR
Intervention: Control condition (neutral video)
Number of subjects: 0
Study 10444054 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved saline solutions
Number of subjects: 40
Study 10444054 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline preserved with ethylene‐diamine‐tetraacetic acid (EDTA) in conjunction with sorbic acid
Number of subjects: 40
Study 10444054 — intervention group
Group type: COMPARATOR
Intervention: Unpreserved saline (previously published study)
Number of subjects: 40
Study 8561488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat test dish presented as low-fat
Number of subjects: 16
Study 8561488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat test dish
Number of subjects: 16
Study 8561488 — intervention group
Group type: COMPARATOR
Intervention: Low-fat test dish presented as high-fat
Number of subjects: 16
Study 2190935 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical reduction (Group 1)
Number of subjects: 100
Study 2190935 — intervention group
Group type: COMPARATOR
Intervention: Sarmiento osteotomy and valgus reduction (Group 2)
Number of subjects: 100
Study 380434 — intervention group
Group type: EXPERIMENTAL
Intervention: True hemodialysis
Number of subjects: 7
Study 380434 — intervention group
Group type: COMPARATOR
Intervention: Sham hemodialysis
Number of subjects: 7
Study 31142104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 52
Study 31142104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (A+R)
Number of subjects: 52
Study 31142104 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 52
Study 28400091 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-MF
Number of subjects: 18
Study 28400091 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP-MF
Number of subjects: 18
Study 25378365 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention (contacted by a trained nurse navigator by telephone to discuss colorectal cancer screening)
Number of subjects: 5240
Study 25378365 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 5240
Study 27276758 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) - 12 weeks of aerobic and resistance training for 60 minutes, three sessions per week.
Number of subjects: 32
Study 27276758 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no specific intervention mentioned.
Number of subjects: 32
Study 21828944 — intervention group
Group type: EXPERIMENTAL
Intervention: MGuard stent
Number of subjects: 46
Study 21828944 — intervention group
Group type: COMPARATOR
Intervention: Non-MGuard stent
Number of subjects: 46
Study 19842973 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC-3TC
Number of subjects: 357
Study 19842973 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-FTC
Number of subjects: 357
Study 16723320 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting in circle arrays
Number of subjects: 0
Study 16723320 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting in curved lines
Number of subjects: 0
Study 16723320 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting strategies
Number of subjects: 0
Study 16723320 — intervention group
Group type: EXPERIMENTAL
Intervention: Error types in counting
Number of subjects: 0
Study 14607566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (50 mg every 48 hours) with hMG
Number of subjects: 109
Study 14607566 — intervention group
Group type: COMPARATOR
Intervention: Placebo with hMG
Number of subjects: 109
Study 10791445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole oral suspension
Number of subjects: 305
Study 10791445 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B oral suspension
Number of subjects: 305
Study 8877335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulfon Lyoc in lyophilised tablet form (group 1; n = 40)
Number of subjects: 79
Study 8877335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulfon suspension (group 2; n = 39)
Number of subjects: 79
Study 8877335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulfon Lyoc and Ulfon suspension
Number of subjects: 79
Study 1921400 — intervention group
Group type: EXPERIMENTAL
Intervention: R1 gastrectomy
Number of subjects: 93
Study 1921400 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 gastrectomy
Number of subjects: 93
Study 6356322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 500 mg before breakfast, lunch, supper and 1000 mg on retiring
Number of subjects: 40
Study 6356322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3083505 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (6 mg/day)
Number of subjects: 40
Study 3083505 — intervention group
Group type: COMPARATOR
Intervention: Penicillamine (go slow and low regime)
Number of subjects: 40
Study 3083505 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 40
Study 3083505 — intervention group
Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 40
Study 3083505 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin and Penicillamine
Number of subjects: 40
Study 28027682 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum ointment
Number of subjects: 140
Study 28027682 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea millefolium ointment
Number of subjects: 140
Study 28027682 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 140
Study 28027682 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo ointment)
Number of subjects: 140
Study 26581685 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based protein matrix (0.165 g/kg body mass)
Number of subjects: 60
Study 26581685 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic, nonnitrogenous maltodextrin control
Number of subjects: 60
Study 25549639 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-channel FES
Number of subjects: 48
Study 25549639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-channel FES
Number of subjects: 48
Study 25549639 — intervention group
Group type: COMPARATOR
Intervention: Comfort stimulation
Number of subjects: 48
Study 22348270 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-static chamber (AeroChamber Plus Z-Stat)
Number of subjects: 7
Study 22348270 — intervention group
Group type: COMPARATOR
Intervention: Static chamber (AeroChamber Plus)
Number of subjects: 7
Study 22348270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 7
Study 20230404 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced cumulative anthracycline dose (350 mg/m2) combined with all-trans-retinoid acid (ATRA)
Number of subjects: 81
Study 20230404 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment with arsenic trioxide and stem cell transplantation
Number of subjects: 81
Study 20230404 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-cytarabine regimen
Number of subjects: 81
Study 18713156 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 62
Study 18713156 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg/day
Number of subjects: 62
Study 15925739 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone/17-beta estradiol (DRSP/E2)
Number of subjects: 230
Study 15925739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 12655535 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin after a single dose of intravenous ceftriaxone and amikacin (Group A)
Number of subjects: 135
Study 12655535 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (Group B)
Number of subjects: 135
Study 12655535 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (Group A)
Number of subjects: 135
Study 10827885 — intervention group
Group type: COMPARATOR
Intervention: Placebo substitution for paroxetine
Number of subjects: 0
Study 10827885 — intervention group
Group type: COMPARATOR
Intervention: Placebo substitution for sertraline
Number of subjects: 0
Study 10827885 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruption of fluoxetine
Number of subjects: 0
Study 8648360 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 500 mg twice daily
Number of subjects: 206
Study 8648360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 1498502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant preparation (SF‐RI 1) administered endotracheally (50‐200 mg/kg)
Number of subjects: 34
Study 1498502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant preparation (SF‐RI 1)
Number of subjects: 34
Study 6405437 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alcohol infusion
Number of subjects: 10
Study 31735560 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg plus pomalidomide 4 mg plus dexamethasone 40 mg (20 mg for patients aged ≥75 years)
Number of subjects: 307
Study 31735560 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide 4 mg plus dexamethasone 40 mg
Number of subjects: 307
Study 31735560 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab-pomalidomide-dexamethasone
Number of subjects: 307
Study 31735560 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide-dexamethasone
Number of subjects: 307
Study 30399455 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT) mediated by methylene blue
Number of subjects: 20
Study 30399455 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaler (US)
Number of subjects: 20
Study 27829428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy QueaseEase™ (blend of ginger, lavender, mint and spearmint)
Number of subjects: 39
Study 27829428 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 39
Study 27829428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy QueaseEase™
Number of subjects: 39
Study 25095886 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 158
Study 25095886 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive treatment
Number of subjects: 158
Study 22617578 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral contraceptive pills (gestodene 0.075 mg and ethinyl estradiol 20 microgram) for 6 months
Number of subjects: 38
Study 22617578 — intervention group
Group type: COMPARATOR
Intervention: Cyclic oral contraceptive pills (gestodene 0.075 mg and ethinyl estradiol 20 microgram) for 6 months
Number of subjects: 38
Study 22617578 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral contraceptive pills
Number of subjects: 38
Study 22617578 — intervention group
Group type: COMPARATOR
Intervention: Cyclic oral contraceptive pills
Number of subjects: 38
Study 20223838 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (120 mg intramuscular injection)
Number of subjects: 383
Study 20223838 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 383
Study 20223838 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyarthritis
Number of subjects: 383
Study 18702687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate length adult colonoscope (CF‐240I)
Number of subjects: 918
Study 18702687 — intervention group
Group type: COMPARATOR
Intervention: Long pediatric colonoscope (PCF‐240L)
Number of subjects: 918
Study 15640982 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segment, onset latency-based transcarpal mixed NCV
Number of subjects: 180
Study 15640982 — intervention group
Group type: COMPARATOR
Intervention: Long-segment studies: antidromic wrist-to-digit sensory NCV without subtraction
Number of subjects: 180
Study 15640982 — intervention group
Group type: COMPARATOR
Intervention: Short-segment studies: transcarpal palm-to-wrist mixed NCV without subtraction
Number of subjects: 180
Study 15640982 — intervention group
Group type: COMPARATOR
Intervention: 2 segment studies: antidromic transcarpal sensory NCV with subtraction
Number of subjects: 180
Study 12354441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site right atrial pacing
Number of subjects: 118
Study 11144061 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (specific treatment details not provided)
Number of subjects: 0
Study 11144061 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study 8809925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dynamic exercises
Number of subjects: 0
Study 8809925 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage or short-time exercise programs
Number of subjects: 0
Study 1667693 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion
Number of subjects: 48
Study 6332953 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.05 mg/kg administered 4 to 5 minutes before aortic cross‐clamping
Number of subjects: 98
Study 6332953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined propranolol group
Number of subjects: 98
Study 6332953 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 98
Study 31473932 — intervention group
Group type: EXPERIMENTAL
Intervention: GTO (Getting To Outcomes) implementation support intervention
Number of subjects: 29
Study 31473932 — intervention group
Group type: COMPARATOR
Intervention: CHOICE (control group)
Number of subjects: 29
Study 29725956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacchaflor (S. boulardii 5 × 10^9, Pharmaforce ApS) twice daily
Number of subjects: 1389
Study 29725956 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (not specified)
Number of subjects: 1389
Study 26956679 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally informed intervention including regular postcards, problem solving therapy, patient support, risk management, improved access to primary care, and cultural assessment in addition to usual care.
Number of subjects: 167
Study 26956679 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally informed intervention
Number of subjects: 167
Study 26956679 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 167
Study 24910105 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bilirubin concentrations
Number of subjects: 588
Study 22499404 — intervention group
Group type: EXPERIMENTAL
Intervention: new Chest Physical therapy (nCPT)
Number of subjects: 30
Study 22499404 — intervention group
Group type: EXPERIMENTAL
Intervention: conventional Chest Physical therapy (cCPT)
Number of subjects: 30
Study 22499404 — intervention group
Group type: COMPARATOR
Intervention: aspiration of the upper airways (Control)
Number of subjects: 30
Study 20042424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary transfer of autologous BM cells (4 + or - 1 days after PCI)
Number of subjects: 38
Study 20042424 — intervention group
Group type: COMPARATOR
Intervention: Optimized treatment only (Control group)
Number of subjects: 38
Study 20042424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary transfer of autologous BM cells
Number of subjects: 38
Study 18620023 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100mg
Number of subjects: 45
Study 18620023 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000mg
Number of subjects: 45
Study 18620023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15693921 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 530
Study 15693921 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 530
Study 11804986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban
Number of subjects: 5225
Study 11804986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5225
Study 11804986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban (subgroup with plasma concentrations measured)
Number of subjects: 5225
Study 11715499 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (n=9,373) tested with serum AFP and real time ultrasound every 6 months
Number of subjects: 18816
Study 11715499 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=9,443) received no screening
Number of subjects: 18816
Study 7790671 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2‐65% O2 gas mixture
Number of subjects: 59
Study 7790671 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 59
Study 2218653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 40
Study 2218653 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 40
Study 310269 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (HLI)
Number of subjects: 38
Study 310269 — intervention group
Group type: COMPARATOR
Intervention: Human fibroblast interferon (HFI)
Number of subjects: 38
Study 31279090 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia Self-Management (MSM) intervention
Number of subjects: 320
Study 31279090 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 320
Study 28590370 — intervention group
Group type: EXPERIMENTAL
Intervention: Early improvement at week 2 (defined as a reduction in the YMRS score of at least 20% or 25%)
Number of subjects: 350
Study 28590370 — intervention group
Group type: EXPERIMENTAL
Intervention: Early improvement at week 2
Number of subjects: 350
Study 25599220 — intervention group
Group type: EXPERIMENTAL
Intervention: MoviPrep + neostigmine methylsulfate and glycopyrrolate (MoviPrep+NG)
Number of subjects: 27
Study 25599220 — intervention group
Group type: COMPARATOR
Intervention: MoviPrep alone
Number of subjects: 27
Study 25599220 — intervention group
Group type: COMPARATOR
Intervention: MoviPrep alone (able-bodied group)
Number of subjects: 27
Study 23551402 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg/kg) for 4 weeks
Number of subjects: 100
Study 23551402 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 100
Study 20890683 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 72
Study 20890683 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 72
Study 18284510 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) pre-PVAI and 3 months post-PVAI
Number of subjects: 1221
Study 18284510 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) pre-PVAI
Number of subjects: 1221
Study 18284510 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of EF between patients with and without LAA thrombus
Number of subjects: 1221
Study 18284510 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of LA size between patients with and without LAA thrombus
Number of subjects: 1221
Study 16123763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-related cues exposure during fMRI
Number of subjects: 17
Study 16123763 — intervention group
Group type: COMPARATOR
Intervention: Nonrelapsers (TES above mean and completed treatment)
Number of subjects: 17
Study 16123763 — intervention group
Group type: COMPARATOR
Intervention: Relapsers
Number of subjects: 17
Study 16123763 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological activation during fMRI
Number of subjects: 17
Study 12739123 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy followed by open appendicectomy if necessary
Number of subjects: 0
Study 12739123 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 0
Study 12739123 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy alone
Number of subjects: 0
Study 12739123 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-looking appendix left at laparoscopy
Number of subjects: 0
Study 10969348 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone therapy
Number of subjects: 27
Study 10436992 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid application in group A
Number of subjects: 600
Study 10436992 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid application in group B
Number of subjects: 600
Study 8790522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ultrasonography
Number of subjects: 950
Study 8790522 — intervention group
Group type: COMPARATOR
Intervention: No examination (Control)
Number of subjects: 950
Study 2662234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 76
Study 2662234 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 76
Study 813951 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 300 mg
Number of subjects: 36
Study 813951 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 600 mg
Number of subjects: 36
Study 813951 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen total daily dose 1,200 mg
Number of subjects: 36
Study 813951 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen total daily dose 2,400 mg
Number of subjects: 36
Study 813951 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 7.5 mg
Number of subjects: 36
Study 31218718 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional letter
Number of subjects: 1356
Study 31218718 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational letter
Number of subjects: 1356
Study 31218718 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone reminder
Number of subjects: 1356
Study 31218718 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives
Number of subjects: 1356
Study 31218718 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational meeting
Number of subjects: 1356
Study 31218718 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1356
Study 27932607 — intervention group
Group type: EXPERIMENTAL
Intervention: EG-1962 (800 mg)
Number of subjects: 72
Study 27932607 — intervention group
Group type: EXPERIMENTAL
Intervention: EG-1962
Number of subjects: 72
Study 27932607 — intervention group
Group type: COMPARATOR
Intervention: enteral nimodipine
Number of subjects: 72
Study 25768241 — intervention group
Group type: EXPERIMENTAL
Intervention: QAC surfactant plus daily hypochlorite cleaning
Number of subjects: 0